Member Info for urbansea89

and Avacta have the IP and big recognised manufacturers who will be building product which is already tried and tested in many applications.
Avacta have the opportunity to flex between manufacture and licensing.
Not keen on SKIN solution as being straightforward enough for mass markets and events.
The water testing seems very viable though and sure it would add to the armoury of solutions.

Think the demo solution was ok but the solution is still a bit of a palaver. Shame about the presentation, they missed a golden opportunity to really impress. Glad someone else is dealing with all of that. I'm far happier owning the IP and producing affirmers en mass and licensing the hell out of it globally. It does provide further recognition and evidence that we're sitting on something extraordinary in terms of IP for many years to come.

Spot on Celtics.
I’ve a feeling IT might have held things up and wouldn’t be surprised if the scope of the brief had been broadened/re-defined in some way a while back.
Ooh to be a fly on the walk.

Think the Elisa provides very profound evidence into the hands of the community of what is to come. It may be that the by doing this we are able to drive collaboration and confidence as a backdrop to the RFPs ongoing. It could also accelerate access to international market and importantly manufacturers who will depend on reliable science for the pre-orders.

Thanks K Invest.
This was what was posted yesterday and I believe what you are referring to. Will leave you to decide how credible you really think this is...
Even more happy than I was after I looked at this.
https://m.youtube.com/watch?fbclid=IwAR3WyNm1YbbvDSF94HQeUtu4sdGkOwHpHRfnRMdgr6A-0AWUZYa2HDaMKdE&v=o0d8yASXv1o

It’s on here. I think it’s an extract from the RNS:

https://www.cambridgeindependent.co.uk/business/fresh-hope-of-covid-19-therapy-as-avacta-reveals-its-affimer-reagents-block-key-virus-interaction-9109904/

Probably busy putting fires out and dodging conflicts

They will no doubt know a lot more about this below aswell. It may be that they’ve struck something up with GSK . That truly would be some all round holy grail solution.

Recently GSK invested $250million in Vir Biotechnology Inc to develop potential antibody treatments for Covid-19 by selecting antibodies from recovered patients, and AstraZeneca also recently announced that it would start a programme to find new monoclonal antibodies that block the spike/ACE2 interaction.

Affimer technology from Avacta. (34728886)Affimer technology from Avacta. (34728886)
“There is significant potential for a therapy that could help prevent infection and limit the progression of the disease, providing immediate benefit to patients.

“With a large and well-resourced partner, a neutralising Affimer therapy could potentially be developed more quickly than a vaccine and we believe that the likelihood of success would be high.”

Wouldn't be surprised if the press overall diss Moonshot further. The editors and publishers are very rarely interested in positive stories. They 'll seek out the evidence that suits them and embellish to suit. It's a real drag that so much of the impending and genuine solution is most likely embargoed.
We'll have our day and don't think it's a lot more waiting time.

300% rise by March next year? with the all of the imminent impending progress. Of course it would be a good outcome but it's not aligned with the news, the numbers and the list of deals that are expected long before then.

It means you protect the integrity of a valuable asset and avoid rip of versions masquerading as yours.
It also marks the product as a valuable asset within the company portfolio.
It potentially allows acquisition of product rather than the company.
It allows you to market the product rather than the Company which makes it.
It’s pretty crucial.

Also be good to get news on pharma partner for Affimer reagents blocking the spike-ACE2 binding and preventing the SARS-COV-2 model virus from entering human cells.

It's not at all newsworthy, news is focused in other areas for now, other than on a BB, no one is interested. This lot is a shower and can't imagine why a serious outfit like Avacta would deal with clowns like this. Avacta need to keep a tighter reign on comms amongst partners.
Still, I'm even more happy than before with everything we have (apart from Medusa, who I don't believe are on brand). Took the opportunity provided by the faux pas to buy some more.

Apologies if it’s already been covered. Anyone have knowledge on roughly how long the shelf life/use by date is likely to be for each LFD test?

This Company is doing my head in. I wish they'd get the main test over the line before sending out comms on new deals, without getting the main one over the line first. I love this business, they potentially have the most incredible tech in a generation and wish we'd be given focussed comms on tests we're waiting on that rather than water/toilets in the next few weeks. Please please give us the news we all know is imminent, even if it's a bit of an update.

Extract from P.14 of McNulty doc today. This may be part of the answer to the 'what could be under the bonnet' question.

'Beyond that £686m target enterprise value for the Affimer platform (which, as we have already explained, could
be achievable this year, were a NAf therapy for COVID-19 to progress into clinic), it is simple to see how the
platform could be valued at many multiples of that in just a few short years. One need only consider the cash
consideration of €3.9bn paid by Sanofi for Ablynx only two years ago – or the ~$125bn in global sales per annum
of antibody-based drugs. Avacta has freedom to operate in developing alternative, Affimer-based therapies
wherever there is already existing antibody-based IP. In essence, it has an almost limitless market to target'

Truly incredible opportunity and big thanks for the doc Myles

Urban Sea 89

Good call yesterday 23.18 Ophidian.
This morning's RNS purely formalises where the video had walked us through. Most probably the best piece of Comms Avacta have released recently; honest, solid and intelligent representation of progress and effectively distancing itself from alternatives. It also politely sets out the current woeful position of what is on the market. Solid work and will no doubt take it all the way to a workable global solution relatively quickly now.
I'd be most interested to hear what else is 'under the bonnet' e.g how quickly Avacta could provide testing in the future for other virus's, could their supply model deliver quickly for new strains, could it be developed for more common ailments down the line. Could testing develop and diagnose and to what extent could it treat.
Very happy with where we are and truly impressed by the quality of this Company.

Sounds like the sub optimal tests provide great risk in spreading this virus further and the current 80% guideline is unacceptably low.
Great video and hugely re-assuring to me. Have very little doubt that this will succeed.

They all need their knuckles wrapped and more so the person who agreed to stage this unnecessary fiasco. It represented nothing new for collaboration in the sector. We already knew what those challenges were. It was just seeing them and hearing them talk about it so negatively that made it so awful, particularly Klaus who is a total stock character. I'm still keen despite this show for all the big important reasons and reassured by the CEO and the other big new investors who I hope weren't watching.

he HAS been reading this board